Sebetralstat - KalVista Pharmaceuticals
Discovered by KalVista, sebetralstat is an investigational novel, orally-administered therapy for the on-demand treatment of HAE. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its …
Oral Sebetralstat for On-Demand Treatment of Hereditary …
May 31, 2024 · Oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo.
Sebetralstat - Drugs.com
In KONFIDENT-S, sebetralstat has enabled patients to treat attacks early with a median time from attack onset to treatment of 9 minutes, demonstrated a consistent safety and efficacy profile with KONFIDENT, and included a median time to beginning of …
A single oral administration of sebetralstat rapidly provides near-complete inhibition of plasma kallikrein and blockade of high-molecular-weight kininogen cleavage as early as 15 min, which drives its clinical efficacy.
An investigational oral plasma kallikrein inhibitor for on-demand ...
Feb 11, 2023 · Sebetralstat (KalVista Pharmaceuticals) is a novel oral plasma kallikrein inhibitor that is in development for the on-demand treatment of hereditary angioedema attacks.
Sebetralstat, an oral plasma kallikrein (PKa) inhibitor, was evaluated in KONFIDENT,6 a randomized, double-blind, placebo-controlled, phase 3 crossover trial for on-demand treatment of HAE-C1INH. Compared with placebo, sebetralstat provided significantly faster symptom relief, reduction in attack severity, and complete attack resolution. Figure 1.
Oral Sebetralstat for On-Demand Treatment of Hereditary
Jul 4, 2024 · Oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo. (Funded by KalVista Pharmaceuticals; KONFIDENT ClinicalTrials.gov number, NCT05259917; EudraCT number, 2021-001226-21.).
Oral Sebetralstat for On-Demand Treatment of Hereditary …
Dec 1, 2024 · Sebetralstat administered orally at doses of 300 mg or 600 mg for the on-demand treatment of HAE attacks is superior to placebo and resulted in a faster time to symptom relief, reduction in severity of episodes, and increased percentage of attacks, with complete resolution within 24 hours of administration of trial agent.
Sebetralstat for On-demand Treatment of Hereditary …
A phase 2 trial of sebetralstat, a novel oral plasma kallikrein inhibitor for on-demand treatment in hereditary angioedema (HAE), met its primary endpoint (NCT04208412). KONFIDENT is an international, randomized, double-blind, placebo-controlled, 3-way crossover, phase 3 trial (NCT05259917).
Oral Sebetralstat for Hereditary Angioedema | New England …
May 31, 2024 · On-demand treatments for hereditary angioedema attacks are given parenterally, making adherence a challenge. The investigational oral drug sebetralstat may be an alternative.